Related Experiment Video
Updated: May 7, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
VEGF signal system: the application of antiangiogenesis
Xuewu Liang, Fuming Xu, Xiaoguang Li
1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong 250012, China. wfxu@yahoo.cn.
Abstract:
Among the numerous endogenous promoters of angiogenesis, vascular endothelia growth factor (VEGF) plays a leading role in angiogenesis, which has huge impact on proliferation, survival, migration and permeability of tumor cells. VEGF signal system also becomes remarkable anticancer targets, including VEGF, vascular endothelia growth factor receptor (VEGFR), and VEGF downstream signal pathways. So far, there has been many clinical or approved anticancer drugs that directly or indireactly interfere with VEGF signal system applied in the treatment of various tumors and other diseases associated with pathological angiogenesis. Various kinds of antiangiogenic agents which inhibit VEGF and VEGFR have been developed and discovered gradually, including antibodies, ribozymes and small molecule inhibitors. Meanwhile, the investigation into antiangiogenic agents which block certain signal proteins of VEGF downstream signal pathways attracts the attention of medicinal chemists and enriches the application of antiangiogenic agents. This review will interpret the mysterious VEGF signal system from its molecular structure and probe to the mechanism of the combination of VEGF and its receptors. Furthermore, the detail of VEGF signal pathways will be introduced comprehensively and methodically. In addition, some up-to-date clinical or approved anticancer agents will be clearly tabulated. The binding modes of different kinase inhibitors will be used to explain the SAR of the small molecule inhibitors. Finally, in order to make the readers master VEGF signal system completely, some novel targets and inhibitors which block the downstream signal pathways of VEGF are plainly stated.
Insights
Vascular Endothelial Growth Factor (VEGF) drives angiogenesis and tumor growth. This review details the VEGF signaling system, its role in cancer, and current/novel anti-angiogenic therapies targeting VEGF and its pathways.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, crucial for tumor growth and metastasis.
- The VEGF signaling system, including VEGF, its receptors (VEGFR), and downstream pathways, represents a significant target for anticancer therapies.
- Pathological angiogenesis is implicated in various cancers and other diseases.
Purpose of the Study:
- To provide a comprehensive review of the VEGF signaling system.
- To elucidate the molecular mechanisms of VEGF-ligand and receptor interactions.
- To detail the VEGF downstream signaling pathways and their role in cancer.
Main Methods:
- Review of existing literature on VEGF signaling and anti-angiogenic agents.
- Analysis of molecular structures and binding modes of kinase inhibitors.
- Tabulation of current clinical and approved anticancer agents targeting the VEGF pathway.
Main Results:
- Detailed interpretation of the VEGF signal system, from molecular structure to receptor binding.
- Comprehensive overview of VEGF-mediated downstream signaling pathways.
- Inclusion of up-to-date clinical/approved anticancer agents and their mechanisms, including Structure-Activity Relationships (SAR) of small molecule inhibitors.
Conclusions:
- The VEGF signaling system is a critical target for anti-cancer drug development.
- Various anti-angiogenic agents, including antibodies, ribozymes, and small molecule inhibitors, have been developed.
- Emerging strategies focus on novel targets and inhibitors within the VEGF downstream signaling pathways for enhanced therapeutic efficacy.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Non-Canonical Wnt Signaling Pathways
TGF - β Signaling Pathway

